Revue medicale de Liege 2006-02-01

[Hydrocortisone 17-butyrate (Locoid), a thirty-year ongoing innovative drug].

G E Piérard

Index: Rev. Med. Liege. 61(2) , 128-30, (2006)

Full Text: HTML

Abstract

Since half a century, dermocorticoids represent worthy compounds in dermatological therapy. About thirty years ago, hydrocortisone 17-butyrate was introduced on the Belgian market. This compound combines good efficiency and reduced risk of side effects. Its topical formulations have been enriched over time. The original Locoid lipocream and Locoid Crelo presentations confer remarkable qualities to the product. We report a synopsis of clinical and translational studies devoted to this unique dermocorticoid.

Related Compounds

  • Hydrocortisone
  • Hydrocortisone 17-...

Related Articles:

Functional consequence of the MET-T1010I polymorphism in breast cancer.

2015-02-20

[Oncotarget 6(5) , 2604-14, (2015)]

Cell-cell adhesions and cell contractility are upregulated upon desmosome disruption.

2014-01-01

[PLoS ONE 9(7) , e101824, (2014)]

MYC is a critical target of FBXW7.

2015-02-20

[Oncotarget 6(5) , 3292-305, (2015)]

Inhibitory mechanism of FAT4 gene expression in response to actin dynamics during Src-induced carcinogenesis.

2015-01-01

[PLoS ONE 10(2) , e0118336, (2015)]

Myricetin and naringenin inhibit human squamous cell carcinoma proliferation and migration in vitro.

2014-01-01

[Nutr. Cancer 66(7) , 1257-67, (2014)]

More Articles...